

# **Establishing OELs for Potent and Highly Potent Compounds**

Robert Sussman, Ph.D., DABT  
Managing Principal Eastern Operations,  
SafeBridge Consultants, Inc.

*World HPAPI Summit*  
May 30, 2013

# Agenda

- Introduction
- Process of Occupational Exposure Limit (OEL) development
- Selection of safety and uncertainty factors
- Variability in interpretation of data and selection of endpoints
- Tackling inherent bias in risk assessment (RA)

# What's the Big Deal?

- OELs and other RAs are not precise values
- Regulatory authorities may consider one value “correct”, others “incorrect”
- Derivation should be evaluated as:
  - “consistent with current principles”
  - “not consistent with current principles”
- Applying a consistent and systematic evaluation process will provide confidence in the RA
- Transparency of derivations assures robustness

# Establishing Health-Based OELs

$$\text{OEL (mg/m}^3\text{)} = \frac{\text{NOAEL (mg/kg/day)} \times \text{BW (kg)}}{\text{UF}_C \times \text{MF} \times \alpha \times V \text{ (m}^3\text{)}}$$

where:

OEL	=	Occupational Exposure Limit
NOAEL	=	No-Observed-Adverse-Effect Level
BW	=	Body Weight
UF <sub>C</sub>	=	Uncertainty Factor(s)
MF	=	Modifying Factor
α	=	Bioavailability adjustment
V	=	Volume of air in 8 hour day

# OEL Process

- Collect data
- Select critical endpoint
- Select point of departure (POD)
  - LOAEL / NOAEL
- Select pharmacokinetic factors
- Select safety / uncertainty factors
- Sensitive subpopulations
- Apply values to calculate OEL or other value
- Is this correct?
- How can this be wrong?


# Identification of Critical Endpoint

- Pharmacology / Mode-of-action
- Acute toxicity / Dose-limiting toxicity
- Local tolerability / Sensitization
- Subchronic / Chronic toxicity
- Reproductive / Developmental toxicity
- Mutagenicity / Genotoxicity / Carcinogenicity
- Human safety / Efficacy


# OELs and Critical Endpoint

- Preference for human data
- Chronic studies by the most relevant route
- Most sensitive animal species and organ system (target organ)
- NOAEL vs LOAEL
- Data quality

# Unimodal Population



# Bimodal Population



# Interspecies (Animal to Human)

## Extrapolation

### *Allometric Scaling*

- Uses species surface area/weight to equalize doses
- Surface area is a better factor than body weight – related to relative metabolism of the species
- Factors used for various species are as follows:
  - Dog = 2
  - Monkey = 2-3
  - Rabbit = 3-4
  - Rat = 4-6
  - Mouse = 7-12

# LOEL to NOEL Extrapolation

- Original default = 10
- Compare data from Physicians Desk Reference

$$\frac{\text{Maximum Therapeutic Dose}}{\text{Minimum Therapeutic Dose}} \approx 3$$

# Examples of Ranges for UFs

UF	Default	Range
UF <sub>H</sub>	10	From 3 to 30, depending upon available data
UF <sub>A</sub>	1 – 12	Data from human studies = 1, Mouse = 12
UF <sub>S</sub>	3	Long-term = 1, Acute = 30-100
UF <sub>L</sub>	3	NOAEL = 1, Frank effect = 10-30
UF <sub>D</sub>	3	Extensive database = 1, Limited data 10
UF <sub>C</sub>	-	Usually minimum of 10 to max of 10,000

# Bioavailability Correction Factor


Based on oral data

- If oral low and inhalation high, lower OEL
- OEL set on effects from 100 mg oral dose
- Oral bioavailability = 5%
- Actual inhaled dose causing similar effects = 5 mg

➤ ***Can divide OEL by 20***


$$\alpha = \frac{A_{\text{inh}}}{A_{\text{oral}}} = \frac{1.0}{0.05} = 20$$

# Bioaccumulation




From Sargent & Kirk (1988)

# Bioaccumulation




From Sargent & Kirk (1988)

# Bioaccumulation




From Sargent & Kirk (1988)

# Bioaccumulation




From Sargent & Kirk (1988)

# Bioaccumulation



From Sargent & Kirk (1988)

# Bioaccumulation



From Sargent & Kirk (1988)

# Sensitive Subpopulations

- Healthy worker population
- Clinical trials conducted in “Special Populations”
  - Pediatric (5-17 yrs) and Elderly (>65)
  - Hepatic impairment, renal insufficiency, cardiovascular or respiratory disease
  - Genetic polymorphisms
- Further recommendations for pregnancy, labor and delivery, nursing mothers, concomitant drug use and diseases
- Dose adjustment recommendations provided in package insert can be used to modify LOAEL

# Sources of Variability

- Endpoint and POD (NOAEL / LOAEL)
- Bioavailability and other toxicokinetics
- Sources of uncertainty
- Sensitive subpopulations
- Different RAs account for these variables in different ways
  - How do we standardize these factors?
  - Should we standardize?
  - How is professional judgment standardized?

# Documentation

- Need for transparency
- Verification of robustness
- RA documentation may be requested by regulatory authorities
- No idea how authorities will handle different RA values submitted for same chemical

# Documentation

- Introduction
- Data sources
- Pharmacological mechanism
- Therapeutic indication and dose
- Clinical effects
- PK / PD (including variability)
- Non-clinical data
  - Acute studies
  - Repeat-dose studies
  - Reproductive and developmental studies
  - Genetox and carcinogenicity studies

# Documentation

- Derivation
  - Selection of endpoint and POD
  - PK adjustment (bioavailability & accumulation)
  - Selection of UFs
  - Modifying factors
  - Sensitive subpopulations
  - Calculation
  - ROUNDING!!!!
- Parallel derivations?
- Conclusion

# Sample UF Table

Factor	Default	Value	Comment
UF <sub>H</sub>	10	4.6	Default UF <sub>HD</sub> of 3.16 x chemical-specific UF <sub>HK</sub> of 1.47
UF <sub>A</sub>	1-12	3	Studies performed in monkeys
UF <sub>S</sub>	3	1	No study length factor required for developmental effects
UF <sub>L</sub>	3	3	Default
UF <sub>D</sub>	3	1	Database well developed and includes reproductive and developmental studies
<b>UF<sub>C</sub></b>	<b>-</b>	<b>41</b>	<b>4.6 x 3 x 1 x 3 x 1</b>

# Rounding Convention

- One significant digit
- Second digit ok if:
  - First digit is less than 5, and
  - Value of second digit is 5
- For example:
  - 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90
  - 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 7, 8, 9
  - etc.

# Documentation

- References
- Author qualifications
- Reviewer qualifications
- CVs

# Bias in Risk Assessment

## SOT Code of Ethics

- “Conduct their work with objectivity...”

## AIHA Code of Ethics

- “Deliver competent services... with objective and independent professional judgment...”

***Professional judgment = bias***


# What Do These Animals Weigh?



3.5-9 kg  
8-20 lbs



100-250 kg  
220-550 lbs



1200 kg  
2500 lbs

## Which Are Most Similar?

- West Germany and East Germany (1960s)
- Sri Lanka and Nepal

## Which Are Most *Different*?

- West Germany and East Germany (1960s)
- Sri Lanka and Nepal

# Summary

- Quantitative RA is not an exact science
- The overall process involves applying safety and uncertainty factors to a NOAEL or LOAEL
- It is difficult to standardize professional judgment
- Provide transparent and robust monograph documenting the RA process
- Bias in RA is a good thing!